<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180923041093N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-12-02</date_registration>
      <primary_sponsor>Vice chancellor for research, Kerman university of medical sciences</primary_sponsor>
      <public_title>Effect of spaghula husk mucilage on prevention of chemotherapy-induced mucositis</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of Persian medicine based preparation from spaghula (Plantago Ovata Forsk) husk mucilage on prevention and treatment of oral mucositis  in breast cancer patients receiving adriamycin</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-12-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>20</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/33977</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Crossover, Purpose: Prevention, Randomization description: use of random numbers table, Blinding description: The drug and placebo will coded by a third person (A - B). Therefore, the patient, researchers and outcome evaluators do not know which patient is in the drug group and which patient is in the placebo group. After the completion of the sampling, the third person will offer the codes to the data analyzer.</study_design>
      <phase>3</phase>
      <hc_freetext>Adriamycin induced oral mucositis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: A mixture of (500 ml ispaghula husk and 3 drops of vinegar in 30 cc water) should be kept in the mouth for 1 minute then poured out, three times a day . For 14 days. The intervention begins from the start of the Adriamycin Course and continues until the next course begins. Intervention 2: Control group: placebo: A mixture of (400 mg maltodextrin + 80 mg carbomer +20 mg cinnamon +3 drops of triethanolamine  in 30 cc water) should be kept in the mouth for 1 minute then poured out, three times a day . For 14 days. The intervention begins from the start of the Adriamycin Course and continues until the next course begins.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data will be shared through a supplementary file after unidentified individuals.

When:
Start the access period from 6 months after printing results

To whom:
Researchers and other people can access data if they need it.

Conditions:
For use in review articles, reprogramming and modeling can be used in other studies. In case of need, should be emailed to the programmer.

Where to obtain:
Executor of plan or University

How to obtain:
Email the scheduler (Dr.Setayesh) ,he answers.

Comments:
All information is available to others for the advancement of science.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Sadat Hasheminasab</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Traditional Persian Medicine, Amir Kabir crossroad</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7618843883</zip>
        <telephone>+98 34 3211 0860</telephone>
        <email>hashemifa67@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Setayesh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Traditional Persian Medicine, Amir Kabir crossroad</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7618843883</zip>
        <telephone>+98 34 3211 0860</telephone>
        <email>msetayeshmail@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Breast cancer
Candidate for adriamycin
mucositis in screening course
Remaining two courses of adriamycin with two weeks interval
Age between 17 and 65 years
Life expectancy for more than a year based on physician or team estimates
Physical and mental ability to cooperate in filling in the questionnaire
The desire to participate in the study</inclusion_criteria>
      <agemin>17 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Use alcohol
Use of drugs that affect salivary glands such as antipsychotics, opioids, antihypertensives, antihistamine, diuretics
Use of mouthwashes and artificial saliva and cigarettes
Receiving  Early Radiation in mouth or oropharynx
The history of connective tissue diseases, such as Sjogren, rheumatoid arthritis, lupus
Liver and kidney disease
Major Depression
Diseases that affect salivary glands such as diabetes
Diseases that induce dehydration such as chronic diarrhea
Diseases of the immune system
Recurrent aphthous stomatitis
Receiving Lithium or Levothyroxine for interference with spaghula</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K12.31</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Oral mucositis (ulcerative) due to antineoplastic therapy</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: A mixture of (500 ml ispaghula husk and 3 drops of vinegar in 30 cc water) should be kept in the mouth for 1 minute then poured out, three times a day . For 14 days. The intervention begins from the start of the Adriamycin Course and continues until the next course begins.</i_keyword>
      <i_keyword>Control group: placebo: A mixture of (400 mg maltodextrin + 80 mg carbomer +20 mg cinnamon +3 drops of triethanolamine  in 30 cc water) should be kept in the mouth for 1 minute then poured out, three times a day . For 14 days. The intervention begins from the start of the Adriamycin Course and continues until the next course begins.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Degree of oral mucositis according to WHO scale. Timepoint: Precisely before the intervention, 7 days after the start of intervention and 14 days after the start of intervention (the last day of the intervention). Method of measurement: WHO scale for oral mucositis.</prim_outcome>
      <prim_outcome>Degree of pain due to oral mucositis. Timepoint: Precisely before the intervention, 7 days after the start of intervention and 14 days after the start of intervention (the last day of the intervention). Method of measurement: Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Quality of life. Timepoint: Precisely before the intervention, 7 days after the start of intervention and 14 days after the start of intervention (the last day of the intervention). Method of measurement: OHIP-14 questionnaire.</prim_outcome>
      <prim_outcome>Xerostomia. Timepoint: Precisely before the intervention, 7 days after the start of intervention and 14 days after the start of intervention (the last day of the intervention). Method of measurement: LENT-SOMA scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research, Kerman university of medical sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-09-30</approval_date>
        <contact_name>Ethics committee of Kerman university of medical sciences</contact_name>
        <contact_address>Beginning of Ibn Sina Street, Beginning of Jihad Blvd., Somayeh Road (Tahmasebabad), Kerman Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
